ClinicalTrials.gg
RecruitingNCT06302478Updated Mar 13, 2024

5E Program for Preventing Venous Thromboembolism in Patients With Spinal Cord Disorders

An interventional study of 5E program in Venous Thromboembolism, Spinal Cord Diseases and Spinal Cord Injuries, sponsored by Khon Kaen University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Khon Kaen University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by May 2024, 2 years 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Venous Thromboembolism with a site in Thailand — 1 open to participants now, 1 under way, none of them phase 3. Venous Thromboembolism · Thailand.

Planned enrollment
13th of 14
42 · median 658
Started
2024
the only one that year
No phase
Only one
of the 15
Registered
15th of 15
by date
Lead sponsor
1 of 15
Khon Kaen University

Among the 15 studies in Venous Thromboembolism with a site in Thailand, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is the only one with no phase, and was the 15th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

1 of the 15 studies in Venous Thromboembolism with a site in Thailand is open now.

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Venous Thromboembolism with a site in Thailand, or all of them as a file.
02

Study summary

The goal of this quasi-experimental study is to examine the effects of a venous thromboembolism prevention program, or "5E" program, on the rates of venous thromboembolism in patients with spinal cord disorders. The main questions it aims to answer are:

  • Will participants receiving the 5E program have lower rates of venous thromboembolism compared to those receiving the usual care?
  • Will participants receiving the 5E program have lower scores of venous thromboembolism signs and symptoms compared to those receiving the usual care?
  • Will the average thigh and calf circumferences of participants before and after receiving the 5E program be different?

Participants in the intervention group will receive the 5E program, including

  • Education: health education regarding venous thromboembolism prevention
  • Elevation: leg elevation of 10-20 degrees
  • Exercise: ankle exercises
  • Enough fluid: adequate fluid uptake
  • Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission
03

Conditions studied

  • Venous Thromboembolism
  • Spinal Cord Diseases
  • Spinal Cord Injuries
  • Nurse's Role
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caprini scores of 5-8 and >8
  • Able to communicate in the Thai language
  • Willing to participate in this study

Exclusion criteria

Exclusion Criteria:

  • Alteration of consciousness
  • Experiencing complications, including neurogenic shock and autonomic dysreflexia
  • Being pregnant
  • Having fluid restriction
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    5E Program

    Participants in the 5E program group will receive 7-day nursing interventions.

    Behavioral: 5E program

  • No intervention
    Usual Care

    Participants in the control group will receive 7-day usual care interventions, including health education regarding signs and symptoms of venous thromboembolism and IPC use if the participants experienced muscle power as grade 0.

Interventions

  • Behavioral5E program

    Participants in the 5E program group will receive 7-day nursing interventions including * Education: health education regarding venous thromboembolism prevention * Elevation: leg elevation of 10-20 degrees * Exercise: ankle exercises * Enough fluid: adequate fluid uptake * Early application of intermittent pneumatic compression (IPC): IPC use within 48 hours after admission

06

What researchers measure

Primary outcomes

  1. The rate of venous thromboembolism

    The diagnosis of venous thromboembolism is confirmed by a Doppler ultrasound scan of the femoral vein and popliteal vein by a physician working at the study site. The physician will record the results in the data record form.

    Time frame: The day before implementing the intervention and at 7 days after implementing intervention

Secondary outcomes

  1. Signs and symptoms of deep venous thrombosis and pulmonary embolism

    The Well's Score for deep venous thrombosis (DVT) includes clinical parameters: active cancer or palliative (+1), paralysis (+1), recently bedridden for more than 3 days (+1), localized tenderness (+1), entire leg swelling (+1), calf swelling more than 3 cm compared with asymptomatic leg (+1), pitting edema (+1), previous DVT documented (+1), collateral superficial veins (non-varicose) (+1), and alternative diagnosis (-2). The Modified Well's Score for pulmonary embolism (PE) includes the following criteria: clinical signs and symptoms of DVT (3); an alternative diagnosis is less likely than PE (3); a heart rate greater than 100 (1.5); immobilization for 3 or more consecutive days (1.5); previous objectively diagnosed PE or DVT (1.5); hemoptysis (1); and malignancy (1).

    Time frame: The day before implementing the intervention and Day 1 - Day 7 after implementing intervention

  2. Thigh and calf circumference

    Thigh and calf circumferences will be measured in centimeters using the standardized measuring tape. The assistant researcher will record the results in the data record form.

    Time frame: The day before implementing the intervention and Day 1 - Day 7 after implementing intervention

07

Study locations

1 of 1 sites recruiting
  • Chaiyaphum Hospital
    Chaiyaphum, 36000, Thailand
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for May 2024, 2 months after the start.

Of 65 non-industry interventional studies with no phase under Venous Thromboembolism, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 57. This study's planned 2 months is below that.

Counting every sponsor, half of 70 studies reached it within 31 months; a quarter within 19 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2024
First posted
Mar 8, 2024
StartActual
Mar 12, 2024
Primary completionEst.
May 30, 2024
CompletionEst.
Oct 31, 2024
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06302478
Responsible party
Wiphawadee Potisopha (Principle Investigator, Khon Kaen University) — Principal investigator
First posted
Mar 8, 2024
Start date
Mar 12, 2024
Primary completion
May 30, 2024 (estimated)
Completion
Oct 31, 2024 (estimated)
Last update
Mar 13, 2024

Study contacts

Wiphawadee Potisopha, Ph.D.
Contact
wiphpo@kku.ac.th
+660954291592

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion